Genetic polymorphisms in the E2 glycoprotein of chikungunya virus (2014-2023) and their potential implications for immunity and vaccine design
International Journal of Infectious Diseases·
- DOI
- 10.1016/j.ijid.2025.108193
- PMID
- 41238172
- PMCID
- —
- OpenAlex
- W4416229896
- Study type
- Journal article
- Publisher
- Elsevier BV
- Article type
- journal-article
- Integrity
- current
Why this research matters now
The findings may inform assessment of chikungunya vaccine targets and preparedness planning because variation in the E2 glycoprotein could affect interpretation of immune recognition and viral biological functions. The abstract does not establish effects on vaccine effectiveness, transmission, disease severity, or outbreak occurrence.
Structured evidence summary
Research question
The study examined genetic polymorphisms in chikungunya virus circulating in Brazil and worldwide from 2014 to 2023, focusing on conservation of experimentally validated neutralizing-antibody epitopes in the E2 glycoprotein and the possible relevance of substitutions to vaccine development and epidemic preparedness.
Study design
The study used sequence-based analysis of chikungunya virus E2 glycoprotein sequences, assessed conservation of experimentally validated epitopes, identified potentially biologically significant amino acid substitutions, and mapped these substitutions onto a three-dimensional envelope-protein model.
Population and setting
The analysis covered chikungunya virus isolates or sequences from Brazil and worldwide, spanning 2014 to 2023. The supplied abstract does not specify the number of sequences, sampling sites, or participant characteristics.
Main findings
Known neutralizing-antibody epitopes were reported to have limited conservation in Brazilian isolates and across global genotypes. The analysis also identified numerous substitutions at E2 sites associated with antibody recognition and cellular-receptor binding, particularly in domains A and B.
Public-health relevance
The findings may inform assessment of chikungunya vaccine targets and preparedness planning because variation in the E2 glycoprotein could affect interpretation of immune recognition and viral biological functions. The abstract does not establish effects on vaccine effectiveness, transmission, disease severity, or outbreak occurrence.
Important limitations
The supplied material does not report explicit study limitations. This summary is limited to the supplied single-article abstract and metadata; the original paper is required for decision-grade assessment of sequence selection, analytical methods, validation, and interpretation of the predicted biological significance of substitutions.
GIDS interpretation
The article is discoverable in the supplied metadata through chikungunya, Brazil, and vaccination classifications. It provides genomic and vaccine-design context but does not, on the supplied evidence, confirm or characterize a live surveillance signal.
Related GIDS surveillance
Literature context does not validate, explain, or change a surveillance signal. Exact and contextual relationships are shown separately.
Evidence relationships
This article has 8 auditable classifier relationships to diseases, places, topics, and study design.